ZA202104786B - Deutetrabenazine for the treatment of dyskinesia in cerebral palsy - Google Patents
Deutetrabenazine for the treatment of dyskinesia in cerebral palsyInfo
- Publication number
- ZA202104786B ZA202104786B ZA2021/04786A ZA202104786A ZA202104786B ZA 202104786 B ZA202104786 B ZA 202104786B ZA 2021/04786 A ZA2021/04786 A ZA 2021/04786A ZA 202104786 A ZA202104786 A ZA 202104786A ZA 202104786 B ZA202104786 B ZA 202104786B
- Authority
- ZA
- South Africa
- Prior art keywords
- deutetrabenazine
- dyskinesia
- cerebral palsy
- treatment
- directed
- Prior art date
Links
- MKJIEFSOBYUXJB-VFJJUKLQSA-N (3r,11br)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one Chemical compound C1CN2C[C@@H](CC(C)C)C(=O)C[C@@H]2C2=C1C=C(OC([2H])([2H])[2H])C(OC([2H])([2H])[2H])=C2 MKJIEFSOBYUXJB-VFJJUKLQSA-N 0.000 title abstract 2
- 208000012661 Dyskinesia Diseases 0.000 title abstract 2
- 206010008129 cerebral palsy Diseases 0.000 title abstract 2
- 229950005031 deutetrabenazine Drugs 0.000 title abstract 2
- 239000002207 metabolite Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779232P | 2018-12-13 | 2018-12-13 | |
| US201962801450P | 2019-02-05 | 2019-02-05 | |
| PCT/US2019/066150 WO2020123900A1 (en) | 2018-12-13 | 2019-12-13 | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202104786B true ZA202104786B (en) | 2023-12-20 |
Family
ID=69173404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/04786A ZA202104786B (en) | 2018-12-13 | 2021-07-08 | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11324732B2 (enExample) |
| EP (1) | EP3893876A1 (enExample) |
| JP (1) | JP2022519007A (enExample) |
| KR (1) | KR20210114946A (enExample) |
| CN (1) | CN113395966A (enExample) |
| AU (1) | AU2019395250A1 (enExample) |
| BR (1) | BR112021011386A2 (enExample) |
| CA (1) | CA3123393A1 (enExample) |
| CL (1) | CL2021001554A1 (enExample) |
| IL (1) | IL283920A (enExample) |
| MX (1) | MX2021007063A (enExample) |
| SG (1) | SG11202106344SA (enExample) |
| TW (1) | TWI784220B (enExample) |
| WO (1) | WO2020123900A1 (enExample) |
| ZA (1) | ZA202104786B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022519007A (ja) * | 2018-12-13 | 2022-03-18 | オースペックス ファーマシューティカルズ インコーポレイテッド | 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン |
| US20240197714A1 (en) * | 2021-04-15 | 2024-06-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| JP2024514873A (ja) * | 2021-04-15 | 2024-04-03 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | デューテトラベナジンおよびｃｙｐ２ｄ６阻害剤の併用投与のための方法 |
| WO2024090922A1 (ko) | 2022-10-24 | 2024-05-02 | 주식회사 디자인셀 | 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ591615A (en) * | 2008-09-18 | 2012-07-27 | Auspex Pharmaceuticals Inc | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| AU2015200243B2 (en) * | 2009-06-24 | 2016-09-29 | Egalet Ltd | Controlled release formulations |
| US20120003330A1 (en) * | 2010-06-01 | 2012-01-05 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| JP6362601B2 (ja) | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| PL3265085T3 (pl) * | 2015-03-06 | 2022-11-07 | Auspex Pharmaceuticals, Inc. | Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi |
| TWI772382B (zh) * | 2017-03-15 | 2022-08-01 | 美商奧斯拜客斯製藥有限公司 | 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途 |
| JP2022519007A (ja) * | 2018-12-13 | 2022-03-18 | オースペックス ファーマシューティカルズ インコーポレイテッド | 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン |
-
2019
- 2019-12-13 JP JP2021534126A patent/JP2022519007A/ja active Pending
- 2019-12-13 KR KR1020217021438A patent/KR20210114946A/ko not_active Abandoned
- 2019-12-13 TW TW108145866A patent/TWI784220B/zh active
- 2019-12-13 BR BR112021011386-0A patent/BR112021011386A2/pt not_active Application Discontinuation
- 2019-12-13 CN CN201980089635.4A patent/CN113395966A/zh active Pending
- 2019-12-13 WO PCT/US2019/066150 patent/WO2020123900A1/en not_active Ceased
- 2019-12-13 SG SG11202106344SA patent/SG11202106344SA/en unknown
- 2019-12-13 CA CA3123393A patent/CA3123393A1/en active Pending
- 2019-12-13 US US16/713,917 patent/US11324732B2/en not_active Expired - Fee Related
- 2019-12-13 AU AU2019395250A patent/AU2019395250A1/en not_active Abandoned
- 2019-12-13 EP EP19839001.5A patent/EP3893876A1/en not_active Withdrawn
- 2019-12-13 MX MX2021007063A patent/MX2021007063A/es unknown
-
2021
- 2021-06-11 CL CL2021001554A patent/CL2021001554A1/es unknown
- 2021-06-12 IL IL283920A patent/IL283920A/en unknown
- 2021-07-08 ZA ZA2021/04786A patent/ZA202104786B/en unknown
-
2022
- 2022-04-12 US US17/718,441 patent/US20220409597A1/en not_active Abandoned
-
2023
- 2023-06-28 US US18/343,197 patent/US20240082225A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021011386A2 (pt) | 2021-08-31 |
| EP3893876A1 (en) | 2021-10-20 |
| JP2022519007A (ja) | 2022-03-18 |
| US11324732B2 (en) | 2022-05-10 |
| CA3123393A1 (en) | 2020-06-18 |
| CN113395966A (zh) | 2021-09-14 |
| TWI784220B (zh) | 2022-11-21 |
| KR20210114946A (ko) | 2021-09-24 |
| US20200188371A1 (en) | 2020-06-18 |
| MX2021007063A (es) | 2021-12-10 |
| IL283920A (en) | 2021-07-29 |
| WO2020123900A1 (en) | 2020-06-18 |
| US20220409597A1 (en) | 2022-12-29 |
| SG11202106344SA (en) | 2021-07-29 |
| TW202034917A (zh) | 2020-10-01 |
| CL2021001554A1 (es) | 2022-02-11 |
| US20240082225A1 (en) | 2024-03-14 |
| AU2019395250A1 (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551427A1 (en) | Epinephrine spray formulations | |
| PH12018501330A1 (en) | Methods and systems for providing stimuli to the brain | |
| MX2021007063A (es) | Deutetrabenazina para el tratamiento de la discinesia en la paralisis cerebral. | |
| GEP20217317B (en) | Combination therapy for the treatment of cancer | |
| TWD196866S (zh) | 超音波治療控制台 | |
| EP4272839A3 (en) | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | |
| PH12022551035A1 (en) | Siglec-9 ecd fusion molecules and methods of use thereof | |
| EP4640237A3 (en) | Macrophage-based therapy for use in the treatment of acute liver injury | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2023007680A (es) | Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina. | |
| GB201710822D0 (en) | Methods and medical uses relating to the treatment of hypoglycaemia | |
| MY200803A (en) | Mpo inhibitors for use in medicine | |
| WO2019179823A8 (en) | Lactobacillus fermentum for treating fructose-related diseases | |
| MX2019001337A (es) | Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer. | |
| WO2020032902A3 (en) | Aksolotl blastema for use in the treatment of wounds and burns | |
| MX2019015448A (es) | Metodo para la prevencion de trombosis de desviacion de la arteria sistemica a pulmonar. | |
| MX2018011607A (es) | Sultiame para el tratamiento de apnea del sueño. | |
| PH12020551185A1 (en) | Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation | |
| EA202190891A1 (ru) | Композиции и способы для контролируемой стимуляции яичников | |
| AR122244A1 (es) | Métodos para el tratamiento de la discinesia en la parálisis cerebral | |
| EA202191665A1 (ru) | Дейтетрабеназин для лечения дискинезии при церебральном параличе | |
| NZ705229A (en) | Pharmaceutical formulations containing ipidacrine and their use for the treatment of disorders of potency and disorders of other forms of sexual activity | |
| AU201813182S (en) | Plantar Fasciitus Strengthening Pad |